RNAC FY 2019 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+639.4% YoY

Gross Profit

$7M100.0% margin

Operating Income

-$52M-785.6% margin

Net Income

-$55M-829.0% margin

EPS (Diluted)

$-36.46

Cash Flow

Operating Cash Flow

-$51M

Free Cash Flow

-$51M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$100M

Total Liabilities

$91M

Stockholders' Equity

$8M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$903,000	+639.4%
Gross Profit	$7M	$903,000	+639.4%
Operating Income	-$52M	-$65M	+19.3%
Net Income	-$55M	-$65M	+15.3%